Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Profit & Loss 
Valuation 
Analyst Note 
Balance Sheet 
Cash Flow 
Financial Ratio 
Qtr. Results 
News 
About
Fermenta Biotech Ltd (FERMENTA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506414 NSE: FERMENTA Pharmaceuticals & Drugs | Small Cap | Fermenta Biotech Share Price
₹444.75 12.15 (2.81%)
As on 27-Jul'26 10:19
Fermenta Biotech Ltd (FERMENTA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 506414 NSE: FERMENTA Pharmaceuticals & Drugs | Small Cap | Fermenta Biotech Share Price
₹444.75 12.15 (2.81%)
As on 27-Jul'26 10:19
Key Metrics
Valuation Multiples
Market Cap
₹1,273 Cr.
Current Price
₹444.8
52-Week Low / High
₹256 / 480
TTM EPS
₹21.8
TTM Sales
₹450 Cr.
Book Value per Share
₹142.7
P/E Ratio
19.81
Higher than its 5-year historical median
Industry PE
52.9
Price to Book (P/B)
3.03
Higher than its 5-year historical median
Price to Sales (P/S)
2.83
Higher than its 5-year historical median
EV/EBITDA
11.80
In line with its 5-year historical median
Dividend Yield
0.84%
Profitability Efficiency
Return on Equity (ROE)
16.09%
Outperforms industry median
Return on Capital Employed (ROCE)
19.90%
Outperforms industry median
Return on Assets (ROA)
10.08%
Operating Profit Margin
20.4%
Net Profit Margin
14.28%
Gross Profit Margin
22.9%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
4.58%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-8.1%
Net Profit Growth (1 Year)
-
-4.94%
Asset Quality
Promoter Holding
64.09%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹405 Cr.
Equity
₹14.7 Cr.
Face Value
₹5
All Time Low / High
₹4.90 / 480.00
Check Before You Invest
Quality
Somewhat GoodValuation
FairCheck Valuation charts
Price Trend
Strong
Is Fermenta Biotech Ltd a good quality company?
Fermenta Biotech Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Fermenta Biotech Ltd performance compare with that of its Peers?
Revenue growth of Fermenta Biotech Ltd vs industry peers?
Fermenta Biotech Ltd revenue CAGR is 3.85%, compared to the industry median CAGR of 5.34%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Fermenta Biotech Ltd?
Promoters hold 64.09% of the Fermenta Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Fermenta Biotech Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 22.3% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Fermenta Biotech Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -8.5% | -7.5% | 43.5% | 13.8% | 14.5% | 9.9% | -6.2% | 2.6% | 19.1% | 19.9% | - |
| Value Creation Index ⓘ | -1.6 | -1.5 | 2.1 | 0.0 | 0.0 | -0.3 | -1.4 | -0.8 | 0.4 | 0.4 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 5.5 | 12.5 | 405 | 301 | 373 | 388 | 329 | 307 | 431 | 450 | 450 |
| Sales YoY Gr. | - | 126.6% | 3,134.8% | -25.7% | 24.1% | 4.1% | -15.2% | -6.6% | 40.2% | 4.6% | - |
| Adj EPS ⓘ | -6.6 | -7.2 | 42 | 21.8 | 17.7 | 9.6 | -10.3 | -4.6 | 22.8 | 17.4 | 21.8 |
| YoY Gr. | - | NA | NA | -48.1% | -18.8% | -46.1% | -208.3% | NA | NA | -23.9% | - |
| BVPS (₹) ⓘ | 32.6 | 23.5 | 86.7 | 106.3 | 124.3 | 132.2 | 111.9 | 104.4 | 130.2 | 146.4 | 142.7 |
| Adj Net Profit ⓘ | -18.3 | -19.9 | 116 | 62.9 | 51.1 | 27.6 | -29.8 | -13.1 | 66.6 | 49.8 | 64 |
| Cash Flow from Ops. ⓘ | -9.1 | 1.3 | 90.5 | 29.8 | 63 | 50.4 | 124 | 105 | 33.8 | 82.6 | - |
| Debt/CF from Ops. ⓘ | -4.9 | 107.9 | 2.3 | 7.4 | 3.6 | 4.7 | 1.8 | 1.3 | 3.2 | 1.3 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 63.1% | 3.9% | 11% | 4.6% | ||||
| Adj EPS ⓘ | NA | -0.4% | NA | -23.9% | ||||
| BVPSⓘ | 18.2% | 3.3% | 9.4% | 12.4% | ||||
| Share Price | 22.8% | 7.1% | 45.4% | 18.5% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -21.2 | -25.8 | 73.6 | 22.4 | 15 | 7.2 | -8.2 | -4 | 19.2 | 12.4 | 15.1 |
| Op. Profit Mgn % ⓘ | -154 | -26.5 | 35.5 | 23 | 25.7 | 19.8 | 12.1 | 12.3 | 24.3 | 20.4 | 20.2 |
| Net Profit Mgn % ⓘ | -331.3 | -159.2 | 28.6 | 20.9 | 13.7 | 7.1 | -9.1 | -4.3 | 15.5 | 11.1 | 14.3 |
| Debt to Equity ⓘ | 0.5 | 2.2 | 0.9 | 0.7 | 0.6 | 0.6 | 0.7 | 0.4 | 0.3 | 0.3 | 0 |
| Working Cap Days ⓘ | 1,020 | 520 | 111 | 304 | 308 | 355 | 383 | 320 | 245 | 286 | 138 |
| Cash Conv. Cycle ⓘ | -16 | -20 | 35 | 129 | 141 | 168 | 171 | 117 | 88 | 125 | 55 |
Profit And Loss
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6 | 13 | 405 | 301 | 373 | 388 | 329 | 307 | 431 | 450 |
| Operating Expenses ⓘ + | 14 | 24 | 277 | 232 | 278 | 311 | 290 | 270 | 331 | 359 |
| Operating Profit ⓘ | -9 | -11 | 128 | 69 | 95 | 77 | 39 | 37 | 100 | 92 |
| Operating Profit Margin (%) | -154.0% | -90.1% | 31.6% | 22.8% | 25.4% | 19.8% | 11.9% | 12.2% | 23.2% | 20.4% |
| Other Income ⓘ + | 1 | 2 | 26 | 14 | 7 | 8 | 8 | 8 | 13 | 24 |
| Interest ⓘ | 6 | 11 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 12 |
| Depreciation ⓘ | 3 | 4 | 12 | 15 | 19 | 24 | 24 | 24 | 23 | 21 |
| Profit Before Tax ⓘ | -18 | -23 | 121 | 48 | 63 | 43 | -58 | -5 | 74 | 89 |
| Tax ⓘ | 0 | 1 | 11 | -16 | 11 | 12 | -1 | 14 | 7 | 25 |
| Profit After Tax | -18 | -24 | 110 | 64 | 52 | 30 | -57 | -19 | 68 | 64 |
| PAT Margin (%) | -331.0% | -193.0% | 27.3% | 21.2% | 13.9% | 7.8% | -17.3% | -6.1% | 15.7% | 14.3% |
| Adjusted EPS (₹) | -6.7 | -8.8 | 40.1 | 22.1 | 18.0 | 10.5 | -19.8 | -6.5 | 23.2 | 22.4 |
| Dividend Payout Ratio (%) | -3.10% | -2.40% | 1% | 22.70% | 13.90% | 11.90% | -6.30% | -19.30% | 10.80% | 16.70% |
Valuation of Fermenta Biotech - Standalone
Analyst's Notes
No data found!
Balance Sheet
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 90 | 65 | 249 | 307 | 358 | 381 | 323 | 301 | 380 | 420 | |
| Debt + | 38 | 138 | 195 | 206 | 207 | 212 | 185 | 110 | 96 | 99 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 1 | 2 | 43 | 47 | 46 | 46 | 52 | 53 | 64 | 64 | |
| Others Liabilities ⓘ | 17 | 18 | 44 | 12 | 108 | 123 | 107 | 109 | 101 | 51 | |
| Total Liabilities ⓘ | 146 | 223 | 532 | 572 | 719 | 762 | 667 | 573 | 641 | 634 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 8 | 12 | 104 | 126 | 250 | 220 | 228 | 261 | 223 | 217 | |
| CWIP ⓘ | 1 | 0 | 22 | 71 | 57 | 35 | 45 | 2 | 16 | 13 | |
| Investments ⓘ | 31 | 108 | 76 | 72 | 13 | 13 | 15 | 4 | 4 | 12 | |
| Inventories | 0 | 0 | 88 | 114 | 133 | 130 | 110 | 79 | 94 | 131 | |
| Trade Receivables | 0 | 0 | 66 | 77 | 96 | 118 | 67 | 77 | 120 | 137 | |
| Cash Equivalents | 1 | 2 | 91 | 32 | 41 | 31 | 55 | 57 | 62 | 18 | |
| Others Assets ⓘ | 104 | 100 | 87 | 79 | 130 | 216 | 146 | 94 | 122 | 107 | |
| Total Assets ⓘ | 146 | 223 | 532 | 572 | 719 | 762 | 667 | 573 | 641 | 634 | |
Cash Flow
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -9 | 1 | 91 | 30 | 63 | 50 | 124 | 105 | 34 | 83 |
| Cash Flow From Investing Activity ⓘ + | 20 | -89 | -97 | -39 | -44 | -32 | -64 | -15 | 0 | -44 |
| Cash Flow From Financing Activity ⓘ + | -13 | 88 | 12 | -48 | -1 | -22 | -41 | -91 | -51 | -42 |
| Net Cash Flow ⓘ | -2 | 1 | 6 | -57 | 18 | -4 | 19 | -1 | -17 | -4 |
Financial Ratio
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -21.25 | -31.3 | 72.78 | 23.36 | 15.63 | 8.18 | -16.19 | -6 | 19.85 | 16.09 |
| ROCE (%) | -8.47 | -7.52 | 43.46 | 13.83 | 14.54 | 9.85 | -6.18 | 2.56 | 19.07 | 19.9 |
| Asset Turnover Ratio | 0.04 | 0.07 | 1.07 | 0.54 | 0.58 | 0.52 | 0.46 | 0.5 | 0.71 | 0.71 |
| PAT to CFO Conversion(x) | N/A | N/A | 0.83 | 0.47 | 1.21 | 1.67 | N/A | N/A | 0.5 | 1.3 |
| Working Capital Days | ||||||||||
| Receivable Days | 13.90 | 9.80 | 29.70 | 86.90 | 85 | 100.60 | 102.80 | 85.90 | 83.70 | 104.30 |
| Inventory Days | 0 | 0 | 79.10 | 122.20 | 120.60 | 123.40 | 132.80 | 111.90 | 73.40 | 91.30 |
| Payable Days | 0 | 0 | 89.50 | 200 | 137.10 | 115.50 | 140.60 | 181.70 | 145.90 | 152.10 |
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Fermenta Biotech Ltd FAQs
The current trading price of Fermenta Biotech on 27-Jul-2026 10:19 is ₹444.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 26-Jul-2026 the market cap of Fermenta Biotech stood at ₹1,273.2 Cr
The latest P/E ratio of Fermenta Biotech as of 26-Jul-2026 is 19.81.
The latest P/B ratio of Fermenta Biotech as of 26-Jul-2026 is 3.03.
The 52-week high of Fermenta Biotech is ₹480.0 and the 52-week low is ₹256.4.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Fermenta Biotech is ₹450 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Fermenta Biotech Ltd is a average quality company.
The key valuation ratios of Fermenta Biotech Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Fermenta Biotech Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Fermenta Biotech Ltd
Fermenta Biotech an established enterprise with a rich seven-decade history, operates across diverse sectors, including pharmaceuticals, animal feed, nutrition, integrated biotech, environmental solutions and real estate. A key focal point of the company’s expertise lies in the comprehensive manufacturing of Vitamin D3. The Company maintains a sustainable supply chain, providing a notable advantage in the contemporary global market.
The company’s array of Vitamin D3 variants is finely balanced to meet the requirements of both human and animal nutrition, rendering them applicable across a broad spectrum of uses. In addition to Vitamin D3 products, the company engages in the production of APIs for muscle relaxants and anti-flatulent applications. The Company also pioneers the development of innovative enzymes crucial for manufacturing active pharmaceutical ingredients, alongside offering environmental solutions for wastewater treatment and management.
The strategic possession of legacy properties in Thane and Worli, Mumbai, serves as a lucrative source of income for the company. This supplementary revenue stream complements the core business activities, reinforcing the Company’s financial position. Through a development agreement with Mextech Property Developers LLP, the company is poised to construct residential-cum-commercial buildings on its free-hold Thane land and would acquire affordable luxury residential apartments from Mextech on an area sharing basis.
Furthermore, the company has undertaken sale transactions for its IT/ITES building, Thane One. As of the report date, the company has successfully divested a significant portion of the IT/ITES building to third parties. The proceeds from these transactions were judiciously utilized to retire outstanding loans associated with the IT/ITES building.
Business area of the company
The company is engaged in the business of manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations and environmental solution products and renting and selling of properties. The Company caters to both domestic and international markets. The company also has strategic investments in subsidiaries primarily dealing in manufacturing and marketing bulk drugs.
Business Segments
- Vitamin D and niche APIs
- Nutrition
- Integrated biotechnology
- Environment solutions
- Real Estate
Awards
- 2025: Pride of Maharashtra Award
- 2024: Fi India Awards
- 2023: Excellence in Pharma Supply Chain Award
- 2021: Indian Pharma Award
- 2020: Business Leader of The Year Awards
- 2020: Hindustan Times Thane Ratna Award
- 2019: Business Excellence Awards
- 2019: Hindustan Times Thane Ratna Award
- 2018: Indian Pharma Award
Milestones/ History
- 1951: Established International Franchises Private Ltd. to focus on the toll manufacturing of pharmaceutical products.
- 1963: Formed joint venture with Philips Duphar SV
- 1967: Commenced the commercial manufacture of Vitamin D
- 1980: After Solvay acquired Philips Duphar SV, it became the new joint venture partner.
- 1986: Established the company to manufacture enzymes used as catalyst in antibiotic manufacturing.
- 2002: Demerged the pharmaceutical business to Solvay.
- 2003: Consolidated all manufacturing at kullu by expanding the facility to include Vitamin D and other products.
- 2011: Commenced the second plant for manufacturing Vitamin D at Dahej.
- 2012: The company introduced its latest catalyst Fermase PA 850 for Penicillin G Acylase and enhanced the production capacity of Vitamin D resin in Dahej.
- 2014: Launched Vitamin D 100 CWD to cater to the food and dietary nutraceutical supplements market.
- 2016: Enhanced Vitamin D capacity at Dahej. Launched a new version of Vitamin D 500 feed grade powder.
- 2017: Obtained EDQM’s CEP certification for its Vitamin D manufacturing facility in Dahej; and received FSSC 22000 and BRC food safety approvals for both plants.
- 2019: Completed the amalgamation of DIL Limited and Fermenta Biotech Limited (combined entity was renamed as Fermenta Biotech Limited). Incorporated a wholly owned subsidiary called Fermenta Biotech GmbH in Germany. Integrated backwards to manufacture cholesterol, the key starting material of Vitamin D.
- 2020: Introduced fish oil cholesterol for aquaculture nutrition. Established a wholly owned subsidiary named Fermenta Biotech USA LLC in the USA. Acquired a controlling stake in AGD Nutrition, a US-based vitamin company, through Fermenta Biotech USA LLC and renamed it as Fermenta USA LLC.
- 2021: Launched Vitamin AD2 for oil fortification.
- 2022: Signed a binding term sheet with Mextech Property Developers LLP for the development of a land parcel in Thane. Fermenta commissioned its fortified rice kernel manufacturing facility in Pennepalli, Andhra Pradesh.
- 2023: Commissioned its customised food premixing plant in Kullu, Himachal Pradesh.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
